Applied Biosystems/MDS Analytical Technologies Launches New Mass Spectrometry Tools to Advance Public Health and Safety

Applied Biosystems, a division of Life Technologies Corporation (NASDAQ:LIFE), and its mass spectrometry joint-venture partner, MDS Analytical Technologies, a business unit of MDS Inc. (TSX:MDS) (NYSE:MDZ), today announced the commercial availability of new mass spectrometry tools to help laboratories in a variety of industries advance their efforts to improve public health and safety.

Applied Biosystems, a division of Life Technologies Corporation (NASDAQ:LIFE), and its mass spectrometry joint-venture partner, MDS Analytical Technologies, a business unit of MDS Inc. (TSX:MDS) (NYSE:MDZ), today announced the commercial availability of new mass spectrometry tools to help laboratories in a variety of industries advance their efforts to improve public health and safety. The Cliquid^® 3.0 Software application and mTRAQ^® triplex reagents are designed to enhance food and water contaminant testing, forensic drug screening and protein biomarker research.

Cliquid^® 3.0 Software is an automated software application for contaminant testing and forensic analysis. It enables scientists to identify unknown compounds, expanding the scope of Cliquid software to identify the greatest number of compounds and driving the life-science industry's most comprehensive solution for food and water contaminant testing as well as forensic drug screening for emerging variations of illicit drugs. mTRAQ^® triplex reagents are a set of chemical reagents that label proteins in complex samples for targeted quantitation. They make biomarker verification more accurate, doubling the throughput of analysis, which is expected to accelerate the use of increasing numbers of biomarkers in clinical settings.

These tools, which are optimized for Applied Biosystems/MDS Analytical Technologies mass spectrometers, including the SCIEX 5500 Systems and SCIEX TOF/TOF 5800 System, enable scientists to increase their ability to use mass spectrometry systems to identify and quantify compounds or contaminants. For example, food testing laboratories can detect unknown contaminants that may be present in the food supply, while forensic laboratories may be able to identify new designer street drugs in forensic investigations. In the proteomics field, researchers can more rapidly verify and validate biomarkers to support their potential use in clinical settings, including the emergence of personalized medicine.

Laura Lauman, President of Life Technologies' Mass Spectrometry Systems Division
"Scientists in a variety of industries are continuing to employ the power of mass spectrometry to advance their efforts in improving public health and safety. Applied Biosystems/MDS Analytical Technologies continues to support these scientists by providing them with innovative technologies that deliver complete workflow solutions, including industry-leading platforms, software and applications."

Andy Boorn, President of MDS Analytical Technologies
"Applied Biosystems/MDS Analytical Technologies continues to drive new standards for mass spectrometry-based software applications to maximize the innovation of our platforms. We are evolving our technologies to provide the highest-performing tools, responding to customer requirements to expand the capabilities of laboratories."

Additional Resources
Food Testing Solutions
Biomarker Solutions

About Applied Biosystems Products
Applied Biosystems is a global leader in providing innovative instrument systems to accelerate academic and clinical research, drug discovery and development, pathogen detection and forensic DNA analysis. Applied Biosystems, along with Invitrogen - a leading provider of platform independent, essential life science technologies for disease and drug research, bioproduction and diagnostics - is part of Life Technologies. Applied Biosystems and Invitrogen products are used in nearly every major laboratory in the world. For more information, please visit: www.appliedbiosystems.com and www.invitrogen.com.

About Life Technologies
Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: www.lifetechnologies.com.

Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.